Skip to content
Search

Latest Stories

Centred Solutions appoints new chief commercial officer to drive business expansion

Ashley Kilgas joins Centred Solutions as chief commercial officer
Ashley Kilgas joins Centred Solutions as chief commercial officer

Ex-Alliance Healthcare sales director Ashley Kilgas joins Centred Solutions

Pharmacy hub and spoke specialists, Centred Solutions, has further strengthened its team with a key new appointment as the company expands its business.

Ashley Kilgas, formerly sales director at Alliance Healthcare, has joined the company’s executive team as chief commercial officer.


An expert in sales leadership and customer relations with vast experience working in the healthcare and pharmacy sector, Kilgas will be tasked with building a high-performing commercial team to drive value for customers.

Having worked closely with Centred Solutions on previous projects, Ashley already has an in-depth knowledge of the business.

Expressing his excitement about his new role, Ashley said: “Centred Solutions is a pharmacy technology and automation company, with a tremendous amount of opportunity in front of it. There is currently nobody in the market with the same knowledge, expertise or product offering around hub and spoke.

“While the company is still in its infancy, it is growing rapidly, and I am looking forward to working with the team to further strengthen and grow the business to support those working in pharmacy.”

The company has seen significant growth in its UK customer base in the past 18 months, with key players in the pharmacy market adopting its hub and spoke solutions, including hospital home care, care home pharmacies, and community pharmacies.

With new legislation expected to expand the use of hub and spoke, this customer base is anticipated to grow even further.

“It’s an incredibly exciting time to be joining the team as we look to support pharmacies in creating capacity to take on more clinical roles,” Ashley said.

“I’m looking forward to getting out and about over the coming weeks and months to meet our existing customers across the country. I’m also looking forward to connecting and working with other pharmacy businesses that are looking to transform their existing pharmacy dispensing processes so they can create efficiencies and spend more time on face-to-face patient care,” he added.

Todd Siegel, CEO of Centred Solutions, welcomed Ashley’s appointment, stating “I’m absolutely delighted to have Ashley join the team in this key position.

He comes to us with a strong background in executive sales leadership and fostering relationships which he has developed over many years working in UK pharmacy.”

Ashley will be responsible for managing the company’s sales and marketing team as they develop their global footprint.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less